摘要
目的观察国产双氢青蒿素哌喹片治疗恶性疟疾的临床效果。方法在援尼日尔共和国工作期间采用随机分组的方法,将224例恶性疟疾患者分为治疗组和对照组,各112例,治疗组口服双氢青蒿素哌喹片(商品名为科泰复,每片含双氢青蒿素40mg、磷酸哌喹320mg),首剂2片,8、24和32h分别服2片,一个疗程共8片;对照组用双氢青蒿素片(商品名为科泰新,每片60mg),每天1片,首剂加倍,7d为1疗程,共8片。观察和记录病例的临床症状和药物的副作用。结果治疗组和对照组的临床治愈率为100%和96.4%,两组差异无统计学意义(P>0.05);平均退热时间为(36.16±13.32)和(40.42±15.63)h,两组差异有统计学意义(P<0.05),治疗组短于对照组;复燃率为3.6%和13.4%。两组差异有统计学意义(P<0.01),治疗组低于对照组。结论国产双氢青蒿素哌喹片治疗非洲恶性疟疾效果明显,临床治愈率高,退热时间缩短,复燃率降低,无明显毒副作用,可作为治疗普通型恶性疟疾的首选药物。
Objective To assess the therapeutic efficacy of dihydroartemisinin-piperaquine tablet, （trade name ： Ketaifu,40/320mg） made in China in treatment of Plasmodium falciparum malaria. Methods There 224 patients with faleiparum malaria in Public of Niger were randomly assigned to treatment group and control group ,each consisted of 112 eases. The treatment group received a 4-dose course of Ketaifu over 32 hours. And the control group received a 7-days course of dihydroartemisinin tablets （60mg tablets） over 7days. Results The clinical cure rate was 100% in treatment group and 96.4% in control group,without sinificantly statistical difference between the two groups （P〉0.05）. The mean time of fever clearance and recrudescence rate were （36.16±13.32） hour and 3.6% in treatment group and （40.42±15.63） hour and 13.4% in control group, respectively, showing significantly statistical difference on mean time of fever clearance（P〈0.05） and recrudescence rate （P〈0.01） between the two groups. Conclusion The dihydroartemisinin-piperaquine tablets made in China shows a high cure rate,short time of fever clearance,low recrudescence rate and no conspicuous side effect in treatmetn of faleiparum malaria in Africa.
出处
《中国热带医学》
CAS
2009年第8期1462-1463,共2页
China Tropical Medicine
关键词
恶性疟疾
双氢青蒿素
磷酸哌喹
疗效
Plasmodium falciparum malaria
Dihydroartemisinin
Piperaquine
Therapeutic efficacy
